Javid A Dar
Overview
Explore the profile of Javid A Dar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang J, Gamarra J, Picard N, Zhou M, Pijanowski B, Jacobs D, et al.
Nat Ecol Evol
. 2022 Aug;
6(10):1423-1437.
PMID: 35941205
The latitudinal diversity gradient (LDG) is one of the most recognized global patterns of species richness exhibited across a wide range of taxa. Numerous hypotheses have been proposed in the...
2.
Masoodi K, Eisermann K, Yang Z, Dar J, Pascal L, Nguyen M, et al.
Endocrinology
. 2017 Oct;
158(10):3152-3161.
PMID: 28977599
The androgen receptor (AR) plays a critical role in the development of castration-resistant prostate cancer (CRPC) as well as in the resistance to the second-generation AR antagonist enzalutamide and the...
3.
Masoodi K, Xu Y, Dar J, Eisermann K, Pascal L, Parrinello E, et al.
Mol Cancer Ther
. 2017 Jun;
16(10):2120-2129.
PMID: 28655783
The androgen receptor (AR) is a ligand-dependent transcription factor that controls the expression of androgen-responsive genes. A key step in androgen action, which is amplified in castration-resistant prostate cancer (CRPC),...
4.
Johnston P, Nguyen M, Dar J, Ai J, Wang Y, Masoodi K, et al.
Assay Drug Dev Technol
. 2016 May;
14(4):226-39.
PMID: 27187604
Patients with castration-resistant prostate cancer (CRPC) can be treated with abiraterone, a potent inhibitor of androgen synthesis, or enzalutamide, a second-generation androgen receptor (AR) antagonist, both targeting AR signaling. However,...
5.
Splicing Factor Prp8 Interacts With NES(AR) and Regulates Androgen Receptor in Prostate Cancer Cells
Wang D, Nguyen M, Masoodi K, Singh P, Jing Y, OMalley K, et al.
Mol Endocrinol
. 2015 Sep;
29(12):1731-42.
PMID: 26371515
Androgen receptor (AR) plays a pivotal role in the development of primary as well as advanced castration-resistant prostate cancer. Previous work in our lab identified a novel nuclear export signal...
6.
Eisermann K, Dar J, Dong J, Wang D, Masoodi K, Wang Z
PLoS One
. 2015 Jul;
10(7):e0128495.
PMID: 26176602
The androgen receptor (AR) is a member of the steroid receptor superfamily that regulates gene expression in a ligand-dependent manner. The NTD of the AR plays a key role in...
7.
Dar J, Masoodi K, Eisermann K, Isharwal S, Ai J, Pascal L, et al.
J Steroid Biochem Mol Biol
. 2014 Mar;
143:473-80.
PMID: 24662325
Androgen-independent nuclear localization is required for androgen receptor (AR) transactivation in castration-resistant prostate cancer (CRPC) and should be a key step leading to castration resistance. However, mechanism(s) leading to androgen-independent...
8.
Pascal L, Ai J, Masoodi K, Wang Y, Wang D, Eisermann K, et al.
PLoS One
. 2013 Nov;
8(11):e79542.
PMID: 24260246
ELL-associated factor 2 (EAF2) is an androgen-responsive tumor suppressor frequently deleted in advanced prostate cancer that functions as a transcription elongation factor of RNA Pol II through interaction with the...
9.
Dar J, Eisermann K, Masoodi K, Ai J, Wang D, Severance T, et al.
J Steroid Biochem Mol Biol
. 2013 Oct;
139:16-24.
PMID: 24099702
Nucleocytoplasmic trafficking of the androgen receptor (AR) represents an essential step in androgen action. To determine whether the amino-terminal domain (NTD) contains potential nuclear import and/or export signals, deletion mutants...
10.
Gong Y, Wang D, Dar J, Singh P, Graham L, Liu W, et al.
Endocrinology
. 2012 Oct;
153(12):5716-25.
PMID: 23041672
Androgen receptor (AR) plays a key role in prostate development and carcinogenesis. Increased expression and/or stability of AR is associated with sensitization of prostate cancer cells to low levels of...